Continuous corticosterone delivery via the drinking water or pellet implantation: A comparative study in mice

• Published in: Steroids Vol. 116; pp. 76 - 82
• Main Authors: Gasparini, Sylvia J., Weber, Marie-Christin, Henneicke, Holger, Kim, Sarah, Zhou, Hong, Seibel, Markus J.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.12.2016
• Subjects: Animals; Corticosterone - administration & dosage; Corticosterone - pharmacokinetics; Corticosterone delivery; Cushing Syndrome - blood; Cushing Syndrome - drug therapy; Drinking Water - administration & dosage; Drinking Water - chemistry; Drug Implants - administration & dosage; Drug Implants - pharmacokinetics; Drug Implants - therapeutic use; Glucocorticoid-induced dysmetabolism; Hypercortisolism; Insulin Resistance - physiology; Insulin-resistance; Male; Mice; Osteocalcin - blood; Osteoporosis; Osteoporosis - blood; Osteoporosis - drug therapy; Sarcopenia; Sarcopenia - blood; Sarcopenia - drug therapy; Sarcopenia; Osteoporosis; Corticosterone delivery; Hypercortisolism; Glucocorticoid-induced dysmetabolism; Insulin-resistance
• ISSN: 0039-128X; 1878-5867
• DOI: 10.1016/j.steroids.2016.10.008

•Delivery of corticosterone via the drinking water is inexpensive and adjustable.•It is safe and non-invasive and thus avoids operative stress.•It closely mimics the kinetics of clinical glucocorticoid (GC) therapy.•It reproduces the changes in fat, bone and muscle seen with GC therapy in humans.•It is advantageous over the use of slow-release pellets. In order to investigate the effects of glucocorticoid excess in rodent models, reliable methods of continuous glucocorticoid delivery are essential. The current study compares two methods of corticosterone (CS) delivery in regards to their ability to induce typical adverse outcomes such as fat accrual, insulin resistance, sarcopenia and bone loss. Eight-week-old mice received CS for 4weeks either via the drinking water (25–100μgCS/mL) or through weekly surgical implantation of slow release pellets containing 1.5mg CS. Both methods induced abnormal fat mass accrual, inhibited lean mass accretion and bone expansion, suppressed serum osteocalcin levels and induced severe insulin resistance. There was a clear dose dependant relationship between the CS concentrations in the drinking water and the severity of the phenotype, with a concentration of 50μg CS/mL drinking water most closely matching the metabolic changes induced by weekly pellet implantations. In contrast to pellets, however, delivery of CS via the drinking water resulted in a consistent diurnal exposure pattern, closely mimicking the kinetics of clinical glucocorticoid therapy. In addition, the method is safe, inexpensive, easily adjustable, non-invasive and avoids operative stress to the animals. Our data demonstrate that delivery of CS via the drinking water has advantages over weekly implantations of slow-release pellets. A dose of 50μg CS/mL drinking water is appropriate for the investigation of chronic glucocorticoid excess in mice.